✦ LIBER ✦

Estimating number-needed-to-treat to avoid hypoglycaemic episodes in people with type 2 diabetes: a post-hoc analysis of a prospective randomized controlled trial comparing once-daily insulin glargine with twice-daily NPH insulin

✍ Scribed by Rosenstock, J.; Fonseca, V.; Dain, M.P.; Riddle, M.

Book ID: 123144082
Publisher: Canadian Diabetes Association
Year: 2009
Tongue: English
Weight: 451 KB
Volume: 33
Category: Article
ISSN: 1499-2671
DOI: 10.1016/S1499-2671(09)33016-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A network meta-analysis to compare glyca

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo

✍ Scott, D. A.; Boye, K. S.; Timlin, L.; Clark, J. F.; Best, J. H. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 663 KB

Reduced risk of hypoglycemia with once-d

Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial

✍ Rosenstock, Julio; Fonseca, Vivian; Schinzel, Stefan; Dain, Marie-Paule; Mullins 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 510 KB

Low-Volume Insulin Degludec 200 Units/mL

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial

✍ Gough, S. C. L.; Bhargava, A.; Jain, R.; Mersebach, H.; Rasmussen, S.; Bergensta 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 443 KB

The Efficacy and Safety of Insulin Deglu

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

✍ Meneghini, L.; Atkin, S. L.; Gough, S. C. L.; Raz, I.; Blonde, L.; Shestakova, M 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 842 KB